导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.62% | 4151/4733 |
| 近一周 | -2.88% | 4312/5412 |
| 近一月 | -6.92% | 4327/5369 |
| 近一季 | 1.04% | 779/5180 |
| 近半年 | -12.72% | 3776/4872 |
| 近一年 | -25.77% | 4081/4367 |
| 近两年 | 12.53% | 2767/2942 |
| 近三年 | -12.21% | 2046/2242 |
| 成立以来 | -1.78% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.68% 4244/4961 |
-15.77% 4700/5312 |
- - |
- - |
| 2025 | 15.15% 2567/4813 |
19.05% 120/3635 |
-2.85% 3385/4076 |
15.83% 2770/4524 |
-14.04% 4329/4813 |
| 2024 | 6.94% 1708/3463 |
-4.42% 1661/2808 |
-4.89% 1583/3014 |
28.23% 197/3129 |
-8.27% 2843/3463 |
| 2023 | -22.69% 1938/2656 |
-5.08% 2134/2280 |
-5.34% 1431/2385 |
-5.67% 1354/2515 |
-8.78% 2310/2655 |
| 2022 | -13.28% 323/2207 |
-21.01% 1594/1919 |
19.59% 82/2016 |
-17.87% 1654/2113 |
11.77% 138/2208 |
| 2021 | -16.97% 1167/1822 |
-1.45% 494/1255 |
10.08% 492/1330 |
-14.44% 1370/1466 |
-10.55% 1605/1822 |
| 2020 | 47.95% 190/1250 |
-13.10% 920/1028 |
30.04% 65/1067 |
11.56% 436/1164 |
17.36% 128/1184 |
| 2019 | - - |
- - |
- - |
0.20% 548/850 |
9.78% 195/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 泰康港股通大消费指数C VS. 长安沪深300非周期A(740101) |